Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep 29;9(10):1102.
doi: 10.3390/vaccines9101102.

Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review

Meng Lv  1   2   3 , Xufei Luo  4 , Quan Shen  2   3   5 , Ruobing Lei  2   3   5 , Xiao Liu  4 , Enmei Liu  2   3   6 , Qiu Li  1   2   3 , Yaolong Chen  7   8   9   10   11   12
Affiliations
Review

Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review

Meng Lv et al. Vaccines (Basel). .

Abstract

Aim: To identify the safety, immunogenicity, and protective efficacy of COVID-19 vaccines in children and adolescents.

Methods: We conducted a systematic review of published studies and ongoing clinical studies related to the safety, immunogenicity, and efficacy of COVID-19 vaccine in children or adolescents (aged < 18 years). Databases including PubMed, Web of Science, WHO COVID-19 database, and China National Knowledge Infrastructure (CNKI) were searched on 23 July 2021. International Clinical Trials Registry Platform (ICTRP) was also searched to identify ongoing studies.

Results: Eight published studies with a total of 2852 children and adolescents and 28 ongoing clinical studies were included. Of the eight published studies, two were RCTs, two case series, and four case reports. The investigated COVID-19 vaccines had good safety profiles in children and adolescents. Injection site pain, fatigue, headache, and chest pain were the most common adverse events. A limited number of cases of myocarditis and pericarditis were reported. The RCTs showed that the immune response to BNT162b2 in adolescents aged 12-15 years was non-inferior to that in young people aged 16-25 years, while with 3 μg CoronaVac injection the immune response was stronger than with 1.5 μg. The efficacy of BNT162b2 was 100% (95% CI: 75.3 to 100), based on one RCT. Of the 28 ongoing clinical studies, twenty-three were interventional studies. The interventional studies were being conducted in fifteen countries, among them, China (10, 43.5%) and United States(9, 39.1%) had the highest number of ongoing trials. BNT162b2 was the most commonly studied vaccine in the ongoing trials.

Conclusion: Two COVID-19 vaccines have potential protective effects in children and adolescents, but awareness is needed to monitor possible adverse effects after injection. Clinical studies of the COVID-19 vaccination in children and adolescents with longer follow-up time, larger sample size, and a greater variety of vaccines are still urgently needed.

Keywords: COVID-19; adolescents; children; systematic review; vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Study selection process (WHO: World Health Organization; COVID-19: coronavirus disease 2019; CNKI: China National Knowledge Infrastructure; ICTRP: International Clinical Trials Registry Platform).
Figure 2
Figure 2
Ongoing interventional COVID-19 vaccine trials in children and adolescents worldwide. Color in the figure indicates the number of ongoing vaccine trials in each country.
See this image and copyright information in PMC

References

    1. CDC Vaccines: The Basics. [(accessed on 8 August 2021)]; Available online: https://www.cdc.gov/vaccines/vpd/vpd-vac-basics.html.
    1. The World Bank Population Ages 0–14 (% of Total Population) [(accessed on 8 August 2021)]. Available online: https://data.worldbank.org/indicator/SP.POP.0014.TO.ZS.
    1. Xing K., Tu X.Y., Liu M., Liang Z.W., Chen J.N., Li J.J., Jiang L.G., Xing F.Q., Jiang Y. Efficacy and safety of COVID-19 vaccines: A systematic review. Zhongguo Dang Dai Er Ke Za Zhi. 2021;23:221–228. doi: 10.7499/j.issn.1008-8830.2101133. - DOI - PMC - PubMed
    1. Pormohammad A., Zarei M., Ghorbani S., Mohammadi M., Razizadeh M.H., Turner D.L., Turner R.J. Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Vaccines. 2021;9:467. doi: 10.3390/vaccines9050467. - DOI - PMC - PubMed
    1. McDonald I., Murray S.M., Reynolds C.J., Altmann D.M., Boyton R.J. Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2. NPJ Vaccines. 2021;6:74. doi: 10.1038/s41541-021-00336-1. - DOI - PMC - PubMed

LinkOut - more resources